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ABSTRACT Tumor necrosis factor alpha (TNF-a) is a potent cytokine involved in systemic inﬂammation and
immune modulation. Signaling responses that involve TNF-a are context dependent and capable of stimulating pathways promoting both cell death and survival. TNF-a treatment has been investigated as part of
a combined therapy for acute myeloid leukemia due to its modifying effects on all-trans retinoic acid (ATRA)
mediated differentiation into granulocytes. To investigate the interaction between cellular differentiation
and TNF-a, we performed RNA-sequencing on two forms of the human HL-60/S4 promyelocytic leukemia
cell line treated with TNF-a. The ATRA-differentiated granulocytic form of HL-60/S4 cells had an enhanced
transcriptional response to TNF-a treatment compared to the undifferentiated promyelocytes. The observed TNF-a responses included differential expression of cell cycle gene sets, which were generally
upregulated in TNF-a treated promyelocytes, and downregulated in TNF-a treated granulocytes. This is
consistent with TNF-a induced cell cycle repression in granulocytes and cell cycle progression in promyelocytes. Moreover, we found evidence that TNF-a treatment of granulocytes shifts the transcriptome toward
that of a macrophage. We conclude that TNF-a treatment promotes a divergent transcriptional program in
promyelocytes and granulocytes. TNF-a promotes cell cycle associated gene expression in promyelocytes.
In contrast, TNF-a stimulated granulocytes have reduced cell cycle gene expression, and a macrophage-like
transcriptional program.

Tumor necrosis factor alpha (TNF-a) is a pro-inﬂammatory cytotoxic
cytokine (Sedger and McDermott 2014) which activates the innate
immune response (Mizgerd et al. 2001; Striz et al. 2014; Francisco
et al. 2015), induces migration (Smart and Casale 1994; Vieira et al.
2009) and promotes pro-inﬂammatory cytokine production (Shalaby
et al. 1989; Kagoya et al. 2014). Dysregulation of TNF-a can be a
factor in autoimmune disease (Chu et al. 1991; Palucka et al. 2005)
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and anti-TNF antibodies are used to treat a range of inﬂammatory
disorders (Feldmann 2002; Chowers and Allez 2010; Maxwell et al.
2015). Initially investigated as a cancer therapeutic due to its ability
to promote apoptotic cell death speciﬁcally of tumor cells (ZieglerHeitbrock et al. 1986), systemic TNF-a treatment has failed clinical
trials as a solo cancer therapeutic due to unacceptable levels of toxicity
(Roberts et al. 2011).
TNF-a signaling is complex with numerous and sometimes conﬂicting responses being modulated by interaction with two cell surface
TNF-a receptors, TNFR1 and TNFR2 (Sedger and McDermott 2014).
TNF-a binding can have a wide range of effects via activation of signal
transduction pathways, including all three groups of mitogen activated
kinases (MAPK); extracellular-signal-regulated kinases (ERKs), the
cJun NH2-terminal kinases (JNKs), and the p38 MAP kinases (Sabio
and Davis 2014), which each have complex regulatory effects on the
cellular phenotype (Kim and Choi 2010; Plotnikov et al. 2011). TNF-a
signaling leads to transcriptional upregulation of pro-inﬂammatory
cytokines including IL-6 (Shalaby et al. 1989) and TNF itself (Kagoya
et al. 2014), resulting in pro-inﬂammatory feedback loops (Yarilina et al.
2008). Notably, TNFR1 and TNFR2 have individual and combinatorial

Volume 9 |

August 2019

|

2775

effects on cell death and inﬂammation (Kalb et al. 1996; Rauert et al.
2011; Sedger and McDermott 2014). TNFR1 signaling induces proapoptotic pathways resulting in caspase activation, and pro-survival
Nuclear Factor Kappa B (NFKB) signaling (Ting and Bertrand 2016;
Annibaldi and Meier 2018). This results in hematopoietic cells growing in log phase rapidly undergoing apoptosis in response to TNF-a,
while quiescent cells in stationary phase re-enter the cell cycle on
TNF-a stimulation (Baxter et al. 1999). These apparently conﬂicting
TNF-a responses can be explained by temporal and developmental
effects that include cell type (Ajibade et al. 2013), receptor expression
(Baxter et al. 1999), priming with cytokines or inﬂammatory stimuli
(Erwig et al. 1998; Wang et al. 2006), and cell cycle stage (Darzynkiewicz
et al. 1984).
The HL-60/S4 cell line was derived from an acute promyelocytic
leukemia patient (Gallagher et al. 1979). These promyelocytic cells
can be differentiated into granulocytic or macrophage forms with the
addition of all-trans retinoic acid (ATRA) or 12-O-tetradecanoylphorbol-13-acetate (TPA), respectively (Mark Welch et al. 2017). Differentiation into the granulocytic form slows cell growth (Mark Welch
et al. 2017) and ultimately leads to cell death (Ozeki and Shively
2008). This discovery lead to the clinical use of ATRA as a treatment
for acute promyeloid leukemia (Su et al. 2015). Combined treatment
with ATRA and TNF-a enhances differentiation of myelogenous
leukemia cells, and therefore has been investigated as a synergistic
therapy (Bruserud 2000; Witcher et al. 2003). Notably, ATRAinduced differentiation activates components of the TNF-a signaling
pathway (Witcher et al. 2003).
A previous study demonstrated differential effects of TNF-a treatment on candidate gene expression in HL-60 cells before and after
ATRA treatment (Vondrácek et al. 2001). Here, we investigate the
genome-wide transcriptional response to TNF-a treatment of the promyelocytic and granulocytic forms of HL-60/S4 cells. We identify a
conserved inﬂammatory and apoptotic response to TNF-a treatment
in both promyelocytic and granulocytic cells. We also identify opposing
effects of TNF-a treatment on the expression of cell cycle genes, supporting cell cycle progression in promyelocytes and cell cycle repression
in granulocytes. We propose that the different TNF-a mediated responses arise through sets of genes being responsive to different thresholds of total (endogenous and exogenous) TNF-a levels.
MATERIALS AND METHODS
Cell culture
HL-60/S4 cells (available from ATCC #CCL-3306) were cultured at
37, 5% CO2 in RPMI 1640 (ThermoFisher) supplemented with 10%
fetal bovine serum (Moregate Biotech), 1% penicillin/streptomycin
(ThermoFisher), 1% GlutaMAX (ThermoFisher) and 2mM CaCl2.
As required, cells were differentiated into a granulocytic phenotype
with 1 mM all trans retinoic acid (ATRA) dissolved in ethanol (Sigma
Aldrich) for four days as previously described (Rowat et al. 2013; Mark
Welch et al. 2017; Jacobson et al. 2018b). Cells were centrifuged (200xg,
5 min, room temp.) and suspended (undifferentiated = 1x106 cells/mL;
or differentiated = 5x105 cells/mL) in fresh media (with 1mM ATRA
for differentiated cells). Nuclear morphology and cell surface receptor changes during differentiation are available from Jacobson et al.
2018 (Jacobson et al. 2018b). Hi-C and RNA-seq were used to identify
translocations and other structural variants speciﬁc to HL-60/S4
(Jacobson et al. 2018a). Cells from the same seed-lot were used in all
studies.
Cells (9 · 106 per ﬂask) were incubated at 37 for 2 hr before
addition of 16ng/mL TNF-a or vehicle in triplicate per condition. After
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2 hr treatment, cells in each ﬂask were lysed with TRIzol LS (Life
Technologies), phase separated with chloroform, and RNA extracted
with the Qiagen RNeasy mini kit (Qiagen, 74104). A summary of the
conditions in this study, and the public data from Welch 2017 (Mark
Welch et al. 2017), are shown in table 1.
The full experiment was repeated and samples analyzed with
RT-qPCR of TNF, CDK1, and VCAM1 to validate the RNA-seq results
(see section ‘Real-time quantitative PCR’).
RNA sequencing
Total RNA libraries were prepared by Annoroad Gene Technology
Co., Ltd. (Beijing, China) using ribosomal RNA depletion with RiboZero Magnetic Gold Kit (Human/Mouse/Rat) and sequenced on an
Illumina Hi-seq X 150PE (150 base pair paired end reads).
Publicly available RNA-seq
mRNA-seq data of HL-60/S4 cells in three conditions in quadruplet
(Mark Welch et al. 2017) was downloaded from NCBI (http://
www.ncbi.nlm.nih.gov/bioproject/303179). These conditions are: HL-60/S4
(promyelocytes), HL-60/S4 differentiated with ATRA (granulocytes),
and HL-60/S4 differentiated with TPA (macrophage-like).
RNA-seq analysis
Read quality was conﬁrmed using FastQC v0.11.4. Paired end reads were
aligned to hg38 and gencode annotations v27 using STAR (Dobin et al.
2013) v2.5.3a with default settings. FeatureCounts (Liao et al. 2014)
v1.5.2 was used to aggregate transcripts for gene-level analysis and
quantify the reads with GENCODE (Harrow et al. 2012) annotations
v27. MultiQC (Ewels et al. 2016) was used to summarize FastQC,
STAR, and FeatureCounts outputs (Ewels et al. 2016). Mapping statistics are summarized in table 1.
Expressed genes were ﬁltered (default settings) and differentially
expressed genes (False discovery rate (FDR) , 0.05) identiﬁed in
DEseq2 (Love et al. 2014) v1.16.1. Gene ontology enrichments were
calculated with TopGo (Alexa and Rahnenfuhrer 2016) v2.28.0 using
the weight01 algorithm and the Fisher statistic. Categories containing ,2
genes were removed, and p values adjusted for FDR. Kegg pathway
analysis, GSEA, and enrichment analyses were performed using clusterProﬁler (Yu et al. 2012). Intersects were displayed with Vennerable,
subsets extracted with dplyr (Wikham et al. 2018), and plots were generated with ggplot2 (Wikham 2016) in RStudio (RStudio 2016; R Core
2018).
RNA-seq data were also used to check for mycoplasma contamination, as performed in (Olarerin-George and Hogenesch 2015). All libraries were aligned to the genomes of four common mycoplasma
species known to contaminate mammalian cell culture: Mycoplasma
hominis ATCC 23114 (NC_013511.1), M. hyorhinis MCLD (NC_017519.1),
Mycoplasma fermentans M64 (NC_014921.1) and Acholeplasma laidlawii
PG-8A (NC_010163.1). The fasta genome sequences and genome
annotation ﬁles were downloaded from NCBI Genome, and genome indices were created with STAR 2.6.0c. Due to their small
genome size, the parameter genomeSAindexNbases was adjusted for
each genome to the recommended log2(GenomeLength)/2 – 1. Zero
reads from any of the 12 libraries aligned to any of the four mycoplasma genomes, conﬁrming that our cultures were free from mycoplasma contamination.
Real-time quantitative PCR
Total RNA was isolated using TRIzol LS (Life Technologies). RNA
was quantiﬁed using a NanoDrop spectrophotometer (NanoDrop
Technologies). Isolated RNA was DNase I treated (Life Technologies).

n Table 1 Details of HL-60/S4 RNA-seq datasets. Four conditions in triplicate were generated in this study, while three conditions with
four replicates were analyzed from Welch et al. Cells were undifferentiated (promyelocyte), differentiated with ATRA (granulocyte) or TPA
(macrophage). Promyelocytes and granulocytes in this study were treated with TNF-a or vehicle. The library preparation method in this
study was ribosomal depletion to sequence all long RNAs, while Welch 2017 (Mark Welch et al. 2017) used poly-A enrichment to sequence
mRNA only. ‘Reads sequenced’ indicate the total number of paired-end reads generated per library. ‘Reads mapped’ indicate the number
of read pairs aligned to the human genome with STAR (Dobin et al. 2013). ‘Reads assigned’ indicates the number of mapped reads
assigned to genomic features (e.g., protein coding gene, non-coding RNA) with featureCounts (Liao et al. 2014).
Data
source

Library type

Differentiation
agent

Cell type

Treatment Replicate

New data

Total

None

Promyelocyte None

New data

Total

None

Promyelocyte TNF

New data

Total

ATRA

Granulocyte

None

New data

Total

ATRA

Granulocyte

TNF

Welch 2017

mRNA

None

Promyelocyte None

Welch 2017

mRNA

ATRA

Granulocyte

None

Welch 2017

mRNA

TPA

Macrophage

None

1
2
3
1
2
3
1
2
3
1
2
3
1
2
3
4
1
2
3
4
1
2
3
4

Reads
sequenced

Reads
mapped

Reads
assigned

51,259,672
45,409,486
47,722,497
45,401,741
46,622,711
52,842,736
46,965,601
53,329,425
52,544,954
44,130,932
55,591,032
44,662,624
78,330,794
79,840,457
92,276,843
71,908,445
78,215,359
79,385,831
67,293,855
74,792,543
78,936,655
75,555,764
75,679,506
70,096,915

48,256,979
43,088,708
45,321,199
42,548,543
44,003,082
50,124,478
44,427,313
50,564,062
49,873,305
41,753,860
52,524,970
42,149,334
72,778,198
74,010,895
85,870,266
67,034,452
73,037,649
73,007,606
61,810,327
68,660,444
72,842,622
69,802,997
69,532,640
65,311,735

31,775,702
26,931,181
28,412,920
26,121,834
28,053,460
31,895,061
24,592,785
28,655,822
28,687,969
23,800,117
29,318,607
22,829,189
63,063,700
63,896,640
77,717,651
61,274,376
63,738,330
65,788,452
55,209,128
61,293,657
63,297,008
59,853,678
63,186,748
59,900,363

Dobin, A., C. A. Davis, F. Schlesinger, J. Drenkow, C. Zaleski et al. 2013 STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29: 15–21.
Liao, Y., G. K. Smyth, and W. Shi, 2014 featureCounts: an efﬁcient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30:
923–930.
Mark Welch, D. B., A. Jauch, J. Langowski, A. L. Olins, and D. E. Olins, 2017 Transcriptomes reﬂect the phenotypes of undifferentiated, granulocyte and macrophage
forms of HL-60/S4 cells. Nucleus 8: 222–237.

Single-stranded cDNA was synthesized from 1 mg of RNA using a
High capacity cDNA RT kit (Thermoﬁsher # 4368814), according to
the manufacturer’s protocol. Real-time quantitative PCR analysis was
carried out using predesigned PrimeTime Mini qPCR assays (Integrated DNA Technologies; Supp table 22) on a Lightcycler
480 (Roche). mRNA levels were normalized using reference genes
(GAPDH and COX4I1). Log2 fold changes, standard errors, and conﬁdence intervals were calculated in RStudio (RStudio 2016; R Core
2018) using the delta-delta Ct method (Schmittgen and Livak 2008).
Data availability
TNF-a treatment RNA-seq data are available on GEO, accession
GSE120579. Differentiation RNA-seq data from [30] is publicly available
on NCBI, http://www.ncbi.nlm.nih.gov/bioproject/303179. Analysis of
processed RNA-seq data are available on github, https://github.com/
jacel/TNF_HL60_S4. Supplemental material available at Figshare:
https://doi.org/10.25387/g3.8146097.
RESULTS
In order to investigate transcriptional responses to TNF-a, the promyelocytic cell line HL-60/S4 was differentiated into a granulocytic
form by treatment with ATRA for 96 hr, as described previously
(Jacobson et al. 2018b). Both undifferentiated (promyelocytic) and
differentiated (granulocytic) cells were treated with 16ng/mL TNF-a

in calcium supplemented media for two hours. TNF-a treatment of
promyelocytes and granulocytes were run as independent experiments;
as a consequence, analysis of transcriptional changes following differentiation was not appropriate. However, a recently published study
investigated transcriptional changes following differentiation of promyelocytic HL-60/S4 cells into granulocytes or macrophages (Mark
Welch et al. 2017). We reanalyzed this data for use in comparisons
with the TNF-a response. All genes in both sets of data that were
signiﬁcantly differentially expressed (False discovery rate adjusted
p-value (FDR),0.05) following differentiation or TNF-a treatment
were identiﬁed (Supp table 1). In order to assess the reproducibility
of our data, a subset of differentially expressed genes (TNF, CDK1,
VCAM1) were analyzed by RT-qPCR qPCR in a set of independent
samples treated as above i.e., 6 1 mM ATRA and 6 16ng/mL TNF-a
(Supp table 2). Consistent with RNA-seq analysis, RT-qPCR demonstrated that TNF-a stimulated promyelocytes and granulocytes have
increased levels of TNF and VCAM1. CDK1 increases expression in promyelocytes and decreases expression in granulocytes following TNF-a
treatment.
Gene expression changes After TNF-a treatment of
promyelocytic and granulocytic cells
RNA-seq libraries were aligned using an ultrafast universal RNA-seq
aligner (STAR (Dobin et al. 2013)) and assigned to genes with featureCounts (Liao et al. 2014). DESeq2 (Love et al. 2014) was used to ﬁlter

Volume 9 August 2019 |

Cell Type Speciﬁc TNF-a Responses | 2777

out lowly-expressed genes and performing differential expression analysis. 14,420 genes were analyzed for TNF-a dependent differential
expression in promyelocytes. 21,305 genes were analyzed for TNF-a
dependent differential expression in granulocytes. Principal component analysis of variance stabilized transcripts conﬁrmed clustering
by treatment (Supp ﬁgure 1).
The promyelocytic and granulocytic forms of HL-60/S4 cells both
exhibited strong transcriptional responses to TNF-a treatment (Supp
table 1). In promyelocytes, 1,312 genes were signiﬁcantly increased and
980 signiﬁcantly decreased (FDR adjusted p value , 0.05, Figure 1A).
TNF-a treatment of granulocytes signiﬁcantly increased expression of
3809 genes and decreased expression of 3,597 genes (FDR adjusted p
value , 0.05, Figure 1B). Notably, the granulocytic form had more than
three times the number of signiﬁcantly differentially expressed genes
(Figure 1C). Despite this, there was signiﬁcant overlap in the TNF-a
dependent transcriptional response between the granulocytic and promyelocytic cells (2.5-fold more than expected by chance, P , 1x1025,
bootstrapping). The TNF-a treatment resulted in more genes being
upregulated than downregulated in both the promyelocytic and granulocytic forms of the HL-60/S4 cells (P , 2x10216 and P = 5x1024,
respectively; 2-sample test for equality of proportions).
Genes that were signiﬁcantly differentially expressed after TNF-a treatment in both the promyelocytic and granulocytic forms of HL-60/S4 cells
exhibited strongly correlated log2 fold changes (P , 2x10216, R2 = 0.65).
There was a small subset of differentially expressed genes that
exhibited changes in opposite directions in promyelocytes and granulocytes (Figure 1D). Notably, the effect sizes of conserved gene expression changes were similar, with a slope of 1.08. If the observed
differences in the numbers of differentially expressed (DE) genes
were due to a different magnitude of effect, we would expect to see
a correlation in fold change between genes that were differentially
expressed in one cell type but not the other. However, the fold change
of non-conserved genes did not strongly correlate between cell types
(Figure 1E & F, R2 = 0.038, R2 = 0.15).
Collectively these results suggest that the difference in TNF-a responses is not simply due to granulocytic cells showing enhanced regulation of a conserved set of genes, resulting in a greater number that
are signiﬁcantly differentially expressed. Instead, additional sets of genes
are changing transcriptional activity in TNF-a treated granulocytes.
Functional analysis of the TNF-a response in
promyelocytes and granulocytes
Functional analysis of gene sets is affected by the available gene function
information, and the method of enrichment analysis (Huang et al.
2009). Therefore, we used multiple annotation sources (i.e., Molecular
Signatures Database (MSigDB) hallmark gene sets (Liberzon et al.
2015), gene ontology (GO) (Alexa and Rahnenfuhrer 2016), and Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways (Ogata et al.
1999)) to interrogate the TNF-a response in HL-60/S4 cells and identify robust enrichment results.
Gene set enrichment analysis of promyelocytes and granulocytes
treated With TNF: We ﬁrst interrogated the global gene expression
changes that occurred in the two different cell types after TNF-a treatment. Gene set enrichment analysis (GSEA) is a method that allows
analysis of an entire differential expression dataset without using arbitrary signiﬁcance thresholds (Subramanian et al. 2005). Instead, the
entire dataset is ranked by log2 fold change, and terms are considered
enriched if they are overrepresented at the top or bottom of the ranked
list. This approach allows for a differentiation between functional categories of genes that are upregulated or downregulated after treatment
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(Mootha et al. 2003), and provides an overview of transcriptional
changes.
We performed GSEA of hallmark gene sets (Supp table 3). We found
a strong upregulation response to TNF-a, in both the promyelocytic
and granulocytic forms of the HL-60/S4 cells, that was characterized
by immune and cell death pathways (Figure 2). However, the granulocytic genes that were upregulated were also enriched for terms that
included notch signaling and hypoxia. Transcripts associated with
WNT and beta-catenin signaling were downregulated in promyelocytes (Figure 2).
As observed in the differentially expressed genes, GSEA showed a
strong conserved response with notable divergences between TNF-a
stimulated promyelocytes and granulocytes.
Functional analysis of conserved, cell type-speciﬁc, and opposite
TNF-a responses: In order to further investigate the similarities and
differences in the TNF-a response, we grouped the list of analyzed
genes based on the direction and signiﬁcance of the expression change
in each cell type. Genes that were differentially expressed following
TNF-a treatment were divided into four groups according to the nature of the correlation between the promyelocytic and granulocytic
responses: 1) conserved; 2) promyelocyte-speciﬁc; 3) granulocytespeciﬁc; and 3) opposite responses (Supp table 1). The ﬁrst group
represents the conserved response, i.e., the genes were signiﬁcantly
differentially expressed in the same direction in both promyelocytic
and granulocytic forms of the HL-60/S4 cells. The next two groups
represent cell type-speciﬁc responses – i.e., genes that were only differentially expressed in either promyelocytes or granulocytes in response to TNF-a treatment. The ﬁnal group is comprised of the
157 genes that were signiﬁcantly upregulated in the ﬁrst cell type
and signiﬁcantly downregulated in the other cell type, or vice versa.
Having identiﬁed groups of genes that change in a conserved,
cell-type speciﬁc, and opposite manner, we performed functional enrichment analyses to further investigate the responses to TNF-a in
promyelocytes and granulocytes.
A conserved TNF-a response: Genes that exhibited signiﬁcant
changes in the same direction in response to TNF-a treatment in both
promyelocytic and granulocytic forms of the HL-60/S4 cells were more
frequently upregulated than downregulated (3:1). Notably, this trend
was not maintained for cell type-speciﬁc gene expression changes (promyelocyte-speciﬁc 1.2:1, granulocyte-speciﬁc 0.9:1). There were
nine enriched MSigDB hallmark gene sets (Liberzon et al. 2015) in
the conserved response gene set (Figure 3A, Supp table 4), all of which
are associated with well described effects of TNF-a stimulation; cytokine signaling, inﬂammation, and apoptosis. This was broadly consistent with the results of GSEA (Figure 2). The top three enriched
pathways within KEGG were: NFKB Signaling, NOD-like receptor
signaling, and TNF-a signaling pathways (Supp table 5). The top
10 enriched GO terms included interferon-gamma (IFNg)-mediated
signaling pathway, inﬂammatory response, and positive regulation of
I-kappaB kinase/NFKB signaling (Supp table 6).
In summary, using three different annotation databases and four
different analysis approaches, we have shown that TNF-a treatment of
both promyelocytic and granulocytic forms of HL-60/S4 cells induces a
transcription proﬁle associated with inﬂammatory responses and
NFKB signaling.
Granulocyte-speciﬁc TNF-a responses: The cell type-speciﬁc promyelocytic DE genes had no signiﬁcant enrichments of MSigDB gene
sets, KEGG pathways, or GO terms. Cell type-speciﬁc granulocytic DE
genes were enriched for MSigDB sets related to cell cycle and energetics
(Figure 3B, Supp table 7). The top ﬁve enriched KEGG pathways included Cell Cycle, Protein processing in endoplasmic reticulum, and

Figure 1 Transcriptional changes in
promyelocytic and granulocytic (+ATRA)
forms of HL-60/S4 following two hours
of TNF-a treatment (+TNF). A) The Log2
fold change (log2FC) and adjusted p values of all analyzed genes in promyelocytes with and without TNF-a treatment.
B) The log2FC and adjusted p values of
all analyzed genes in granulocytes with
and without TNF-a treatment. C) There is
a shared and unique transcriptional response to TNF-a treatment of HL-60/S4
promyelocytes and granulocytes. D)
The log2FC of genes that were significantly differentially expressed in both
HL-60/S4 and HL-60/S4+ATRA cells
were positively correlated (R2 = 0.65).
However, there was a small subset of
genes that were anticorrelated. E) The
log2FC of genes that were only differentially expressed in HL-60/S4 cells
did not correlate between HL-60/S4
and HL-60/S4+ATRA after TNF-a treatment (R2 = 0.04). F) The log2FC of
genes that were only differentially
expressed in HL-60/S4+ATRA cells
did not correlate between HL-60/S4
and HL-60/S4+ATRA after TNF-a treatment (R2 = 0.15).

Cellular senescence (Supp table 8). The six enriched GO terms included
cell division, G2/M transition of mitotic cell cycle, protein poly- and
de-ubiquitination, and neutrophil degranulation (Supp table 9). Thus,
granulocytes, but not promyelocytes, exhibited transcriptional changes
in genes involved in cell cycle and protein processing in response to
TNF-a treatment.

Opposite TNF-a responses in promyelocytes and granulocytes:
Genes that were signiﬁcantly differentially expressed in opposite directions in promyelocytes and granulocytes were enriched for G2M

checkpoint and E2F targets within the MSigDB database (Figure 3C,
Supp table 10). Differentially expressed genes in these sets were upregulated in promyelocytes and downregulated in granulocytes, with the
exception of E2F2. CDK1 is included in both of these cell-cycle associated gene sets, and is considered sufﬁcient to drive the mammalian cell
cycle (Santamaría et al. 2007). As described above, the upregulation and
downregulation of CDK1 in promyelocytes and granulocytes respectively was conﬁrmed by RT-qPCR (Supp table 2). The set of genes that
was signiﬁcantly expressed in opposite directions was also enriched for
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Figure 2 Transcriptional changes in promyelocytes
and granulocytes (+ATRA) treated with TNF (+TNF).
Gene set enrichment analysis (GSEA) of genes
represented in the MSigDB Hallmark gene sets [1].
All represented genes were ranked by log2FC, with
no signiﬁcance cutoff. The x axis shows signiﬁcantly
enriched gene sets (FDR , 0.05). The normalized
enrichment score (y axis) indicates whether a given
gene set was overrepresented for transcripts that
exhibited large fold changes. Predicted gene sets
(e.g., TNFA signaling via NFKB, p53 pathway, and
IFNg response) were enriched in both conditions.
No gene sets were enriched in promyelocytes but
not granulocytes. Six gene sets (adipogenesis, estrogen response early and late, hypoxia, IFNa response, and xenobiotic metabolism) were enriched
in granulocytes, but not promyelocytes.

three terms, including mitotic chromosome condensation, within the
GO database (Supp table 11). There was no enrichment for pathways
within KEGG.
The inﬂammatory effects of TNF-a stimulation are shared by promyelocytes, but cell cycle repression and altered protein metabolism are
TNF-a responses speciﬁc to granulocytes.
Granulocytic differentiation increases transcript levels
of TNF and TNF receptors
We set out to investigate how differentiation into the granulocytic form
could modulate the TNF-a response, and identify similarities in the
transcriptional changes that occur during differentiation and acute
TNF-a treatment. We were unable to analyze transcriptional changes
that occurred during differentiation, as promyelocytic and granulocytic
cells were treated with TNF-a in separate experiments. In order to
assess gene expression changes associated with differentiation we analyzed publicly available RNA-seq data of HL-60/S4 cells differentiated
into granulocytes (with ATRA) and macrophages (with TPA). Principal component analysis of variance stabilized transcripts conﬁrmed
clustering by differentiation status (Supp ﬁgure 1C).
Consistent with previous reports (Mark Welch et al. 2017), this
analysis conﬁrmed that TNF expression was upregulated during differentiation into either granulocytic or macrophage forms of HL-60/S4
cells. The magnitude of TNF transcript upregulation was different in
granulocytes (log2 fold change = 1.37) and macrophages (log2 fold
change = 4.08) (Supp table 1). Differentiation also induced changes
in the expression levels of the TNFRs. Consistent with previous observations (Mark Welch et al. 2017), TNFRSF1A gene expression was
increased (log2 fold change = 0.87) after ATRA treatment, but there
was no signiﬁcant change in expression following TPA treatment. By
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contrast, TNFRSF1B gene expression was increased in both conditions
(log2 = 1.59 and 3.30 following ATRA and TPA treatment, respectively). This observed increase in mRNA expression of TNF and both
TNF-a receptors may be one explanation for why granulocytes have an
enhanced transcriptional response to TNF-a, compared to promyelocytes.
We investigated whether TNF-associated genes were enriched for
transcriptional changes associated with differentiation into the granulocytic or macrophage form. We performed a GSEA of the transcriptional changes associated with differentiation into the granulocytic and
macrophage form (Figure 4). As described previously, genes associated
with cell-cycle terms (e.g., MYC targets and G2M checkpoint) were
downregulated, while genes associated with inﬂammatory terms (e.g.,
IFNg response, inﬂammatory response, and indeed TNF-a signaling via NFKB) were upregulated in both differentiation experiments
(Figure 4).
As shown in Welch et al. (Mark Welch et al. 2017), differentiation
into either the granulocytic or macrophage form resulted in higher
inﬂammatory gene expression and lower cell cycle rate.
TNF-a treatment has more shared responses with TPA
treatment than ATRA treatment
TNF-a treatment interacts with ATRA to augment differentiation of
myeloid cells (Bruserud 2000; Witcher et al. 2003), but whether it
enhances the differentiation into granulocytic cells or modiﬁes the
differentiation trajectory is unclear. We compared the transcriptional
changes of TNF-a treated granulocytes with those associated with
differentiation into granulocytes or macrophages.
Gene sets upregulated in TNF-a stimulated granulocytes and differentiated granulocytes or macrophages were enriched for ontological
terms associated with hypoxia and xenobiotic metabolism. Notably,

Figure 3 Gene set overrepresentation in
differential expression subsets of TNF-a
(+TNF) treated promyelocytes and granulocytes (+ATRA). A) Genes that were
signiﬁcantly differentially expressed in
the same direction after TNF-a treatment were overrepresented in several
gene sets canonically associated with
TNF-a response. B) Genes that were
only signiﬁcantly differentially expressed
in granulocytes were overrepresented in
9 gene sets, including 4 cell cycle associated gene sets. They were also overrepresented in the reactive oxygen
species pathway, a neutrophilic response to TNF-a. C) Genes that were
signiﬁcantly differentially expressed in
opposite directions were overrepresented in two cell-cycle associated gene
sets. All differentially expressed hallmark
G2M checkpoint genes were upregulated in promyelocytes, and downregulated in granulocytes cells, with the
exception of E2F2, a transcription factor
that promotes quiescence by binding to
promoters and transcriptionally repressing cell cycle genes [2]. All differentially
expressed E2F target genes were upregulated in promyelocytes, and downregulated in granulocytes.

genes that were upregulated in promyelocytes treated with TNF-a did
not show enrichment for these ontological terms. Notch signaling was
upregulated only after TNF-treatment of promyelocytes or differentiation into macrophages. Intriguingly, both early and late estrogen response genes were upregulated in granulocytes treated with TNF-a,
and macrophages, despite reports that TNF-a acts to oppose estrogen
signaling in breast cancer (Lee and Nam 2008). Four terms were upregulated after TNF-a treatment of granulocytes and differentiation into
macrophages: IL2 stat5 signaling, epithelial mesenchymal transition,
apical junction, and KRAS signaling (genes downregulated by KRAS
activation) (Figure 4).
To further compare the transcriptional changes that occur during
differentiation into different cell types with the effects of TNF-a treatment, we assigned differentiation associated changes into four groups: 1)
conserved; 2) granulocyte-speciﬁc; 3) macrophage-speciﬁc; and 4)
opposite, i.e., signiﬁcantly upregulated in granulocytes and signiﬁcantly downregulated in macrophages, or vice versa (Supp table 1).
The ﬁrst group consists of genes that signiﬁcantly change expression
levels in the same direction after differentiation into either the granulocytic from with ATRA, or the macrophage form with TPA. The

second and third groups contain genes that are differentially
expressed only after differentiation into granulocytes or macrophages, but not both. The fourth group represents genes that are
differentially expressed after differentiation into granulocytes and
macrophages, but are upregulated in granulocytes and downregulated
in macrophages, or vice versa. We analyzed these groups of genes for
enrichment of MSigDB gene sets, KEGG pathways, and GO terms.
GSEA identiﬁed the response that is conserved during differentiation
into granulocytes or macrophages as being characterized by pro-inﬂammatory cytokine associated gene sets (i.e., IFNa, response, IFNg
response, TNF-a signaling via NFKB), and cell cycle associated
gene sets (i.e., G2M checkpoint, MYC targets, and mitotic spindle)
(Figure 5A). This ﬁnding was consistent with what was observed as
being enriched within the KEGG pathways and GO terms (Supp
table 13,14).
Genes that changed expression after differentiation into granulocytes, but not macrophages, were not enriched for MSigDB gene sets
or GO terms, but they were enriched for three KEGG pathways related to protein processing (Protein processing in endoplasmic reticulum, ubiquitin mediated proteolysis, and proteasome; Supp table 15). In

Volume 9 August 2019 |

Cell Type Speciﬁc TNF-a Responses | 2781

Figure 4 Transcriptional changes in promyelocytes differentiated into granulocytes with ATRA or macrophages with
TPA, compared to TNF-a treatment of
promyelocytes and granulocytes. Gene
set enrichment analysis (GSEA) of genes
represented in the MSigDB Hallmark
gene sets [1]. All represented genes were
ranked by Log2FC, with no signiﬁcance
cutoff. The x axis shows signiﬁcantly
enriched gene sets (FDR , 0.05), and
the y axis is calculated from the proportion of genes in the leading edge out of
the number of ranked genes, and out of
the gene set size. All conditions were associated with upregulated inﬂammatory
gene sets, and both differentiation conditions were associated with downregulation of cell cycle gene sets.

contrast, genes that changed expression after differentiation into macrophages, but not granulocytes, were enriched for several MSigDB
gene sets related to cell cycle (Figure 5B, Supp table 16). Enriched
KEGG pathways included metabolism and protein processing (i.e.,
carbon metabolism and protein processing in endoplasmic reticulum),
and the TNF-a signaling pathway (Supp table 17). Enriched GO terms
included cell division, and terms related to RNA and protein regulation (i.e., regulation of transcription, DNA-templated, translational
initiation).
Convergence of transcriptional programs in macrophages and
TNF-treated granulocytes: There are many similarities between the
behaviors of HL-60/S4 cells differentiated into granulocytes and macrophages. However, there are also notable behavioral differences that include
macrophages exhibiting a decreased cell cycle rate, increased survival,
and adhesion to both surfaces and other cells (Mark Welch et al. 2017).
We investigated the genes that were signiﬁcantly differentially
expressed with negatively correlated log2 fold changes after differentiation into granulocytes or macrophages – i.e., in opposite directions.
This gene set was enriched for the IL2/STAT5 signaling, p53 pathway,
and TNF-a signaling MSigDB hallmark terms (Figure 5C). 91% of
these genes (102/112) increased expression after macrophage differentiation, and decreased expression after granulocytic differentiation. 65%
of these genes (70/112) signiﬁcantly increased expression in granulocytes treated with TNF-a, while only 10% (12/112) signiﬁcantly decreased expression (Figure 5C). Six transcription factors (ATF3, BCL6,
FOSL1, KLF4, KLF9, NR4A1) increased expression after macrophage
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differentiation and granulocytes treated with TNF-a, but decreased
expression after granulocytic differentiation, which indicates a shared
change in transcriptional programming. CD83, which is a marker of
transdifferentiation of neutrophils into a dendritic-type cell, increased
in both TNF-a treated cell types (Iking-Konert et al. 2001, 2002). Given
that macrophages and dendritic cells are phenotypically similar (Hume
2008; Hashimoto et al. 2011), CD83 could be considered a marker of
macrophage transdifferentiation.
Collectively our analyses suggest that TNF-a alters the transcriptional proﬁle in HL-60/S4 cells consistent with a transition from a
granulocytic to macrophage phenotype. Consistent with previous observations (Bruserud 2000; Witcher et al. 2003), TNF-a modiﬁes the
differentiation trajectory away from the ATRA induced granulocytic
phenotype, toward a macrophage-like phenotype.
DISCUSSION
TNF-a treatment causes dramatic changes in the transcriptional programs of both promyelocytic and granulocytic HL-60/S4 cells. In this
study we found that ATRA and TPA directed differentiation or TNF-a
treatment of differentiated HL-60/S4 cells resulted in canonical TNF-a
responses involving NKFB signaling, inﬂammatory signaling, p53 and
apoptosis. Due to the reduced proliferation of granulocytic HL-60/S4
cells (Mark Welch et al. 2017) we expected differential cell cycle effects
of TNF-a treatment (Darzynkiewicz et al. 1984; Baxter et al. 1999).
Previous work has shown increased proliferation in quiescent cells,
while proliferating cells exhibited increased apoptosis after TNF-a
treatment (Baxter et al. 1999). In contrast, we saw evidence of cell cycle

Figure 5 Gene set overrepresentation
in differential expression subsets of
promyelocytes differentiated into granulocytes or macrophages. A) Genes
that were signiﬁcantly differentially
expressed in the same direction after
differentiation were overrepresented
in gene sets associated with inﬂammatory signaling and cell cycle. B) Genes
that were only signiﬁcantly differentially expressed in cells differentiated
into macrophages with TPA were predominantly associated with cell cycle.
C) Genes that were signiﬁcantly differentially expressed in opposite directions were overrepresented in
3 gene sets: IL2 STAT5 signaling,
p53 pathway, and TNF-a signaling
via NFKB. A majority of genes in all
categories increased expression after
macrophage differentiation and in
granulocytes treated with TNF-a,
and decrease expression after granulocytic differentiation. Non-signiﬁcant
changes are indicated with gray. Point
colour in (A) and (B) indicate the FDR
adjusted p-value.

repression in granulocytes, particularly at mitotic entry, while proliferating promyelocytes had an increase in cell cycle progression markers
such as CDK1 (Santamaría et al. 2007).
There are several factors that could explain the different responses of
promyelocytes and granulocytes to TNF-a. First, granulocytes have
increased levels of endogenous TNF-a production. Not only does this
increase the total TNF-a the cells are exposed to, but endogenously
produced TNF-a is membrane-bound prior to processing (Horiuchi
et al. 2010). The transmembrane and soluble forms of TNF-a have
different effects (Kadijani et al. 2017), possibly due to the activation of
different TNFRs. Membrane-bound TNF-a can activate both TNFR1
(TNFRSF1A) and TNFR2 (TNFRSF1B), but soluble TNF-a can only
activate TNFR1 (Grell et al. 1995). Granulocytic cells have higher levels
of endogenous TNF expression (therefore, likely higher levels of transmembrane TNF-a) and concurrently higher levels of both TNFRSF1A

and TNFRSF1B gene expression (Theilgaard-Mönch et al. 2005). It has
been previously proposed that increased levels of TNFR2 in granulocytic HL-60 cells explain their resistance to TNF-a induced apoptosis
(Vondrácek et al. 2001). Thus, it may be not just the increased levels of
receptors, but the ratio of TNFR1 to TNFR2 that determines the ultimate response to TNF-a.
The TNFR1 and TNFR2 receptors have uniquely stimulated pathways (Maney et al. 2014; Siegmund et al. 2016), however, the two
receptors also interact to produce a context speciﬁc TNF-a response
(Defer et al. 2007; Naudé et al. 2011). Therefore, manipulating exogenous and endogenous levels of TNF-a or changing the ratio of the
TNFR1 and TNFR2 receptors will provide greater insight into the
phenotypic consequences of TNF-a treatment. Based on our data, we
predict a dose dependent effect of total TNF-a on gene expression,
whereby a low level of TNF-a is sufﬁcient to induce regulation of the
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set of genes seen in the promyelocyte response, while higher levels
of TNF-a are required to repress cell cycle. However, cell cycle repression likely also requires the presence of additional factors (e.g., TNFRassociated factors (Wicovsky et al. 2009)) that are expressed during
differentiation of the HL-60/S4 cells into the granulocytic form.
A reduction in the expression of cell cycle genes at the population
level indicates a change in the proportion of cells at different stages of the
cell cycle. Due to the massive transcriptional changes that occur during
the progression through cell cycle (Peña-Diaz et al. 2013; Boström et al.
2017; Liu et al. 2017a, 2017b), this may obscure other gene regulatory
programs that are associated with alterations to cell function. Despite
this limitation, we found evidence of a subset of TNF-a-regulated genes
that were upregulated in TNF-treated granulocytes and following macrophage differentiation, but downregulated after granulocytic differentiation. These genes encoded a suite of transcription factors, and the
dendritic cell surface marker CD83. Neutrophils that take on characteristics of antigen-presenting cells are often characterized by increased
levels of CD83 (Iking-Konert et al. 2001, 2002), suggesting that TNF-a
may be stimulating transdifferentiation. This is not unprecedented,
as there is evidence that neutrophils have phenotypic plasticity
(Takashima and Yao 2015), and that TNF-a can stimulate transdifferentiation (Bachem et al. 1993; Li et al. 2011; Nishikawa et al. 2013).
However, further functional characterization of TNF-a-treated granulocytic HL-60/S4 cells is required to conﬁrm this hypothesis.
A large-scale TNF-a response experiment treating many different
cell types at various stages of differentiation would allow a network
analysis of the transcriptional responses and annotation-free pathway
discovery (Lu et al. 2017; Liu et al. 2018). This would provide data to
test our hypothesis that total TNF-a exposure correlates with repressive
effects on the cell cycle. If this experiment were performed with single
cell RNA-sequencing it would also enable the investigation of how
individual TNF-a responses result in population-wide changes in cell
cycle gene expression. For instance, do all cells respond to TNF-a
stimulation with cytokine production, G2/M arrest, and apoptosis, or
is there a heterogeneous response between different cells in a population? Moreover, single cell data would allow us to adjust for the cell
cycle transcriptional effects, and identify differences that were previously masked by the population structure of unsynchronized cells.
Despite being one of the most highly studied genes in the human
genome (Dolgin 2017), the complex signaling (Sedger and McDermott
2014) and context dependent effects (Darzynkiewicz et al. 1984; Rauert
et al. 2011; Siegmund et al. 2016) of TNF-a mean that much of its
biology remains unknown. With the increasing accessibility of modern
sequencing technologies and gene editing, high-throughput investigations of the TNF-a response and signaling will yield new results that
enable the contextualization of TNF-a in cancer and immunology.
CONCLUSION
HL-60/S4 cells show a conserved set of core responses to TNF-a treatment irrespective of the differentiation state of the cell. This is expected,
since functional annotations represent canonical pathways and responses. However, granulocytes are more responsive to TNF-a, possibly due to priming from increased endogenous TNF expression, and
increased levels of TNF-a receptors. Transcriptional changes indicate
that TNF-a treatment represses cell cycle progression in granulocytes,
but has the opposite effect on promyelocytes. This effect may be sensitive to the sum total of the exogenous and endogenous TNF-a levels.
Finally, comparisons of transcriptional changes during differentiation
and TNF-a treatment suggest that TNF-a treatment of granulocytes
pushes them toward a macrophage transcriptional program. The context speciﬁc effects of TNF-a are likely mirrored in other models of
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innate immune signaling, and may contribute to the disparities seen
between in vitro and in vivo studies of innate immune signaling.
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